PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest ...

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

Analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of PTC Therapeutics in a report released on ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price ...

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) shot up 6.1% during trading on Monday after Cantor Fitzgerald raised their price target on the stock from $76.00 to $113.00. Cantor ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of ...

PTC Therapeutics (PTCT) shares rallied 9% in the last trading session to close at $50.01. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

PTC Therapeutics has undergone significant changes in recent months, including a major restructuring effort led by CEO Dr. Klein. This initiative has resulted in a 25% reduction in headcount and lower ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a ...